(Q55239961)

28 June 2018

title

In vitro evaluation of the effect of temporary removal of HIV drug pressure. (English)

1 reference

28 June 2018

author

Christophe Pannecouque

2

1 reference

28 June 2018

Erik De Clercq

4

1 reference

28 June 2018

author name string

Witvrouw M

1

1 reference

28 June 2018

Desmyter J

3

1 reference

28 June 2018

Andries K

5

1 reference

28 June 2018

publication date

1 June 2000

1 reference

28 June 2018

published in

Antiviral Research

1 reference

28 June 2018

volume

46

1 reference

28 June 2018

issue

3

1 reference

28 June 2018

page(s)

215-221

1 reference

28 June 2018

Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives)

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Combination therapy for infection due to human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Nucleosides. V. The Monomesylates of 1-(2'-Deoxy-β-D-lyxofuranosyl)thymine1,2

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Combination therapy for HIV-1 infection-overview: preclinical and clinical analysis of antiretroviral combinations

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

Standardisation of primers and an algorithm for HIV-1 diagnostic PCR evaluated in patients harbouring strains of diverse geographical origin. The Belgian AIDS Reference Laboratories.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2800%2900084-X

7 January 2021

10.1016/S0166-3542(00)00084-X

Identifiers

DOI

1 reference

28 June 2018

1 reference

28 June 2018